TD Cowen Remains a Hold on Kohl's (KSS)
In a report released today, Oliver Chen from TD Cowen maintained a Hold rating on Kohl's (KSS – Research Report). The company's shares closed yesterday at $8.04.
Confident Investing Starts Here:
Chen covers the Consumer Cyclical sector, focusing on stocks such as Kohl's, Macy's, and e.l.f. Beauty. According to TipRanks, Chen has an average return of 5.8% and a 52.41% success rate on recommended stocks.
In addition to TD Cowen, Kohl's also received a Hold from Telsey Advisory's Jason Strominger in a report issued yesterday. However, on May 19, J.P. Morgan maintained a Sell rating on Kohl's (NYSE: KSS).
Based on Kohl's' latest earnings release for the quarter ending February 1, the company reported a quarterly revenue of $5.4 billion and a net profit of $48 million. In comparison, last year the company earned a revenue of $5.96 billion and had a net profit of $186 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Philip Morris International Participates in dbAccess Global Consumer Conference
STAMFORD, CT--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE: PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at and on the PMI Investor Relations Mobile Application ( An archived copy of the webcast will be available for approximately one year. 2025 Full-Year Forecast PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on April 23, 2025, of $7.01 to $7.14. Excluding a total 2025 adjustment of $0.35 per share and a favorable currency impact, at then-prevailing exchange rates, of $0.10 per share, this forecast represents a projected currency-neutral increase of 10.5% to 12.5% versus adjusted diluted EPS of $6.57 in 2024, as outlined in the below table. The assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of April 23, 2025. Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of December 31, 2024, PMI's smoke-free products were available for sale in 95 markets, and PMI estimates they were used by 38.6 million adults around the world. The smoke-free business accounted for 42% of PMI's first-quarter 2025 total net revenues. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to 'PMI', 'we', 'our' and 'us' mean Philip Morris International Inc., and its subsidiaries. For more information, please visit and Forward-Looking and Cautionary Statements This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; capital allocation plans; investment strategies; regulatory outcomes; market expectations; business plans and strategies; and dividends. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI. PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco and/or nicotine use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of natural disasters and pandemics on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; recent and potential future tariffs imposed by the U.S. and other countries; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance. PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2024, and the Quarterly Report on Form 10-Q for the first quarter ended March 31, 2025. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.
Business Insider
2 hours ago
- Business Insider
Blueprint Medicines downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (BPMC) to Hold from Buy with a $130 price target after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
2 hours ago
- Business Insider
Blueprint Medicines (BPMC) was downgraded to a Hold Rating at TD Cowen
TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (BPMC – Research Report) to a Hold today and set a price target of $130.00. Confident Investing Starts Here: Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Inozyme Pharma, and Xilio Therapeutics. According to TipRanks, Frahm has an average return of 3.7% and a 39.53% success rate on recommended stocks. In addition to TD Cowen, Blueprint Medicines also received a Hold from J.P. Morgan's Brian Cheng in a report issued today. However, on the same day, Citi reiterated a Sell rating on Blueprint Medicines (NASDAQ: BPMC). The company has a one-year high of $121.90 and a one-year low of $73.04. Currently, Blueprint Medicines has an average volume of 988.3K. Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
